the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients
Recruiting
Phase 2
Interventional Study
Heart Failure
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 1 Month – 18
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 60 (estimated)
- Sponsor
- Ain Shams University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
the study to investigate the efficacy of empagiflozin in pediatric heart failure
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* • Pediatrics (aged 1months-18 years)
* Confirmed HF diagnosis:
HF will be defined by reduced ventricular systolic function (left ventricular ejection fraction by echocardiography) or impaired ventricular filling (pulmonary capillary wedge pressure \> 18 mmHg measured direc…
Contacts